PRTODAY / NewswireToday Free press release distribution service network

More news: Research
Written by / Agency / Source: Aciont, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Aciont® Strengthens Management Team with Industry Leader in Ophthalmic Product Development - Balbir Brar brings 25 years of drug and device development experience to Aciont Inc
Aciont® Strengthens Management Team with Industry Leader in Ophthalmic Product Development

 

NewswireToday - /newswire/ - Salt Lake City, UT, United States, 2010/04/02 - Balbir Brar brings 25 years of drug and device development experience to Aciont Inc.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Aciont Inc. today announced the appointment of Balbir Brar, D.V.M, and Ph.D., to be Vice President, Research and Development. Dr. Brar will oversee the development of Aciont’s Visulex® non-invasive, drug delivery system to treat sight threatening diseases of the back of the eye.

“We are pleased to bring Dr. Balbir Brar—a successful industry leader in ophthalmic research and development who at one time supervised concurrently more than 20 pharmaceutical product development projects—on board to the Aciont team,” said John Higuchi, Aciont’s CEO. “Bal will be instrumental in keeping Aciont focused on achieving our product development milestones efficiently and targeting the important unmet patient and physician needs of our industry.” Dr. Brar has extensive first hand experience of how to design studies to move products through development rapidly while anticipating what can go wrong and what the FDA expects.

Dr. Brar joins Aciont with an extensive background of drug and device pharmaceutical development. For the past six years he has worked as an independent consultant in the drug development field as chief scientific officer/board member for the start-up of various pharmaceutical development ventures. Prior to this, Dr. Brar worked for Allergen Pharmaceutical where he played a major role in the approval of eight major drugs currently on the market including: Alphagam®, Lumigan®, Restasis®, and Botox®. Dr. Brar also contributed to the development of blockbuster drugs at SmithKline & Beckman and Lederle/Wyeth. Dr. Brar has a Ph.D. in Toxicology/Pathology from Rutgers University and D.V.M. from India with finance training from Harvard Business School.

Aciont Inc. (aciont.com) is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic), controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont’s goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont is located in Salt Lake City, Utah.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Aciont, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


Aciont® Strengthens Management Team with Industry Leader in Ophthalmic Product Development

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Jillian Conrad - Aciont.com 
801-359-3461 admin[.]aciont.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Aciont, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Aciont, Inc. / Company Profile


Read Research Most Recent Related Newswires:

DSM Announces Exclusive Partnership with Nanjing Cosmos Chemical Co., Ltd and Plans to Continue Expansion in UV Filters
DSM Launches New Enzyme Solutions At IFT17 to Improve Softness and Moistness of Gluten-free Bread
DSM and Evonik Select Nebraska for Production of Breakthrough Omega-3
Phasor to Develop Next Generation Electronically Steerable Antenna Featuring DSM Dyneema’s Advanced Radome Solution
DSM’s Delvotest® T Antibiotic Residue Test for Milk Validated by Finnish Food Safety Authority
Royal DSM to Make Equity Investment in Amyris with the Purpose of Establishing A Long-term Relationship
DSM Unveils New Beauty Active At NYSCC Suppliers’ Day
Iridea Bio - A New Sustainable Paint Made with DSM’s Decovery® Plant-based Resin
DSM to Showcase A Wide Range of Innovative Composite Solutions
DSM’s New Protective Delvo®Guard Cultures Reduce Food Waste in Dairy
DSM and Evonik Establish Joint Venture for Omega-3 Fatty Acids from Natural Marine Algae for Animal Nutrition
DSM Introduces Dyneema Purity® Black Fiber - The First Black Medical-grade UHMWPE Fiber
Research by German Wildau Technical University Confirms Long-term Performance of Dyneema® Soft Ballistics for Use in Bullet Resistant Vests
DSM Dyneema Wins Significant Patent Case in Israel
Actamax™ Submits IDE to FDA for Pivotal Study on Novel Sprayable Adhesion Barrier Device

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Rapid Recovery





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)